Q-omics provides the consensus-scored SNORA80D profile across patient tissues and cancer cell-line models. SNORA80D expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA80D is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, SNORA80D RNA expression shows 13,490 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, STAD, and ACC as cancer lineages where SNORA80D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA80D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA80D survival associations across molecular data types. SNORA80D RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA80D RNA expression–survival associations across cancer types. High SNORA80D expression shows unfavorable associations in KICH, CESC and PRAD, but favorable associations in HNSC, THYM and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA80D RNA expression.
This table summarizes SNORA80D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA80D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA80D shows higher tumor expression in STAD, HNSC, LIHC, BRCA, CHOL and KIRP. The STAD box plot shows higher SNORA80D RNA expression in tumor versus normal tissue (log2 FC = +0.945, t-test p < 0.001).
This table shows molecular features associated with SNORA80D in patient tissues and cancer cell lines. In patient samples, SNORA80D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
